News Room
News Room
News Room
Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Funding led by Paragon Biosciences, joined by Fidelity Management & Research Company LLC and Valor Equity Partners Chicago, March 23, 2021 – Emalex [...]
CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)
Cell Therapy Platform Seeks to Restore Vision for People with RP Chicago, March 10, 2021— CiRC Biosciences, Inc., a privately held cell therapy [...]
Paragon Biosciences Appoints Jordan Dubow as Chief Medical Officer
Chicago, February 23, 2021—With continued growth in its portfolio of life science companies, Paragon Biosciences announced the appointment of Jordan Dubow, M.D., as [...]
Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform
Its vision restoration technology featured in Nature and New England Journal of Medicine; CiRC is Paragon’s 7th portfolio company, with more in development. [...]
First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering
Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and [...]
Jon DeVries Named Qlarity Imaging Chief Executive Officer
Chicago, September 9, 2020 – Life science innovator Paragon Biosciences announced the appointment of Jon T. DeVries as the new chief executive officer of its [...]
